Stock Events

Stock Events

Gain Therapeutics 

$1.93
38
+$0.17+9.66% Wednesday 06:41

Statistics

Day High
1.93
Day Low
1.93
52W High
-
52W Low
-
Volume
245
Avg. Volume
-
Mkt Cap
69.67M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

19MayExpected
Q3 2025
Q4 2025
Next
-0.16
-0.14
-0.13
-0.11
Expected EPS
-0.1425
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-40.82MNet Income

Analyst Ratings

$8.00Average Price Target
The highest estimate is 9.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow GANX.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals is a competitor because it also focuses on developing treatments for genetic diseases, similar to Gain Therapeutics' focus on genetic disorders.
Biogen
BIIB
Mkt Cap22.63B
Biogen competes in the neurodegenerative diseases space, overlapping with Gain Therapeutics' work on Parkinson's and other CNS disorders.
Sangamo Therapeutics
SGMO
Mkt Cap180.42M
Sangamo Therapeutics is involved in genomic medicine, directly competing with Gain Therapeutics' gene therapy approaches.
PTC Therapeutics
PTCT
Mkt Cap5.4B
PTC Therapeutics operates in the rare diseases sector, making it a direct competitor to Gain Therapeutics, which also targets rare genetic disorders.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics is focused on gene editing, a competitive area for companies like Gain Therapeutics that are involved in genetic disorder treatments.
Novartis
NVS
Mkt Cap237.61B
Novartis is a large pharmaceutical company with a broad portfolio that includes treatments for genetic disorders, competing with Gain Therapeutics' niche focus.
Alnylam Pharmaceuticals
ALNY
Mkt Cap60.25B
Alnylam Pharmaceuticals specializes in RNAi therapeutics for genetic diseases, competing in the same space as Gain Therapeutics.
Sarepta Therapeutics
SRPT
Mkt Cap2.51B
Sarepta Therapeutics is known for its work on Duchenne muscular dystrophy and other genetic disorders, competing with Gain Therapeutics.
Ionis Pharmaceuticals
IONS
Mkt Cap12.03B
Ionis Pharmaceuticals develops RNA-targeted therapies, including for genetic disorders, placing it in direct competition with Gain Therapeutics.

About

Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.
Show more...
CEO
ISIN
US36269B1052

Listings

XNAS
US
GANX
BOATS
BOATS
GANX.BOATS

0 Comments

Share your thoughts

FAQ

What is Gain Therapeutics stock price today?▼
The current price of GANX.BOATS is $1.93 USD — it has increased by +9.66% in the past 24 hours. Watch Gain Therapeutics stock price performance more closely on the chart.
What is Gain Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Gain Therapeutics stocks are traded under the ticker GANX.BOATS.
What is Gain Therapeutics market cap?▼
Today Gain Therapeutics has the market capitalization of 69.67M
When is the next Gain Therapeutics earnings date?▼
Gain Therapeutics is going to release the next earnings report on May 19, 2026.
What were Gain Therapeutics earnings last quarter?▼
GANX.BOATS earnings for the last quarter are -0.11 USD per share, whereas the estimation was -0.14 USD resulting in a +23.61% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Gain Therapeutics revenue for the last year?▼
Gain Therapeutics revenue for the last year amounts to 0 USD.
What is Gain Therapeutics net income for the last year?▼
GANX.BOATS net income for the last year is -40.82M USD.
When did Gain Therapeutics complete a stock split?▼
Gain Therapeutics has not had any recent stock splits.